公开(公告)号：US08173650B2

公开(公告)日：2012-05-08

申请号：US12787613

申请日：2010-05-26

申请人： Georgette Castanedo ,  Bryan Chan ,  David Goldstein ,  Rama Kondru ,  Matthew Lucas ,  Wylie Palmer ,  Stephen Price ,  Brian Safina ,  Pascal Pierre Alexandre Savy ,  Eileen Mary Seward ,  Daniel P. Sutherlin ,  Zachary K. Sweeney

发明人： Georgette Castanedo ,  Bryan Chan ,  David Goldstein ,  Rama Kondru ,  Matthew Lucas ,  Wylie Palmer ,  Stephen Price ,  Brian Safina ,  Pascal Pierre Alexandre Savy ,  Eileen Mary Seward ,  Daniel P. Sutherlin ,  Zachary K. Sweeney

IPC分类号： A61K31/535 ,  C07D413/14

CPC分类号： C07D513/04 ,  C07D487/04 ,  C07D491/04 ,  C07D495/04

摘要： Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, or (iv) X1 is CR7 and X2 is O, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

摘要翻译： 式（I）和（Ib）化合物，其中（i）X1为N，X 2为S，（ii）X1为CR7，X2为S，（iii）X1为N，X2为NR2，或（iv）X1为CR7， X 2为O，包括立体异构体，互变异构体，代谢物及其药学上可接受的盐，可用于抑制PI3K的δ同种型，以及用于治疗由脂质激酶如炎症，免疫学和癌症介导的病症。 公开了使用式I化合物在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

公开(公告)号：US20120178736A1

公开(公告)日：2012-07-12

申请号：US13427081

申请日：2012-03-22

申请人： Georgette Castanedo ,  Bryan Chan ,  David Goldstein ,  Rama Kondru ,  Matthew Lucas ,  Wylie Palmer ,  Stephen Price ,  Brian Safina ,  Pascal Pierre Alexandre Savy ,  Eileen Mary Seward ,  Daniel P. Sutherlin ,  Zachary K. Sweeney

发明人： Georgette Castanedo ,  Bryan Chan ,  David Goldstein ,  Rama Kondru ,  Matthew Lucas ,  Wylie Palmer ,  Stephen Price ,  Brian Safina ,  Pascal Pierre Alexandre Savy ,  Eileen Mary Seward ,  Daniel P. Sutherlin ,  Zachary K. Sweeney

IPC分类号： A61K31/5377 ,  C07D487/04 ,  A61P29/00 ,  A61P37/00 ,  A61P37/06 ,  A61P37/08 ,  A61P1/04 ,  A61P1/00 ,  A61P17/00 ,  A61P11/06 ,  A61P19/04 ,  A61P25/00 ,  A61P7/02 ,  A61P7/00 ,  A61P11/00 ,  A61P17/06 ,  A61P19/02 ,  C07D495/04

CPC分类号： C07D513/04 ,  C07D487/04 ,  C07D491/04 ,  C07D495/04

摘要： Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, or (iv) X1 is CR7 and X2 is 0, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

摘要翻译： 式（I）和（Ib）化合物，其中（i）X1为N，X 2为S，（ii）X1为CR7，X2为S，（iii）X1为N，X2为NR2，或（iv）X1为CR7， X 2为0，包括立体异构体，互变异构体，代谢物和药学上可接受的盐，可用于抑制PI3K的δ同种型，以及用于治疗由脂质激酶如炎症，免疫学和癌症介导的病症。 公开了使用式I化合物在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

公开(公告)号：US20100305096A1

公开(公告)日：2010-12-02

申请号：US12787613

申请日：2010-05-26

申请人： Georgette Castanedo ,  Bryan Chan ,  David Goldstein ,  Rama Kondru ,  Matthew Lucas ,  Wylie Palmer ,  Stephen Price ,  Brian Safina ,  Pascal Pierre Alexandre Savy ,  Eileen Mary Seward ,  Daniel P. Sutherlin ,  Zachary K. Sweeney

发明人： Georgette Castanedo ,  Bryan Chan ,  David Goldstein ,  Rama Kondru ,  Matthew Lucas ,  Wylie Palmer ,  Stephen Price ,  Brian Safina ,  Pascal Pierre Alexandre Savy ,  Eileen Mary Seward ,  Daniel P. Sutherlin ,  Zachary K. Sweeney

IPC分类号： A61K31/5377 ,  C07D495/04 ,  C07D471/04 ,  C07D473/16 ,  A61K31/541 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61P35/00 ,  A61P37/00 ,  A61P9/00 ,  A61P31/12 ,  A61P29/00 ,  A61P3/00 ,  A61P5/00 ,  A61P25/00

CPC分类号： C07D513/04 ,  C07D487/04 ,  C07D491/04 ,  C07D495/04

摘要： Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, or (iv) X1 is CR7 and X2 is O, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

摘要翻译： 式（I）和（Ib）化合物，其中（i）X1为N，X 2为S，（ii）X1为CR7，X2为S，（iii）X1为N，X2为NR2，或（iv）X1为CR7， X 2为O，包括立体异构体，互变异构体，代谢物及其药学上可接受的盐，可用于抑制PI3K的δ同种型，以及用于治疗由脂质激酶如炎症，免疫学和癌症介导的病症。 公开了使用式I化合物在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

公开(公告)号：US08394796B2

公开(公告)日：2013-03-12

申请号：US13427081

申请日：2012-03-22

申请人： Georgette Castanedo ,  Bryan Chan ,  David Goldstein ,  Rama Kondru ,  Matthew Lucas ,  Wylie Palmer ,  Stephen Price ,  Brian Safina ,  Pascal Pierre Alexandre Savy ,  Eileen Mary Seward ,  Daniel P. Sutherlin ,  Zachary K. Sweeney

发明人： Georgette Castanedo ,  Bryan Chan ,  David Goldstein ,  Rama Kondru ,  Matthew Lucas ,  Wylie Palmer ,  Stephen Price ,  Brian Safina ,  Pascal Pierre Alexandre Savy ,  Eileen Mary Seward ,  Daniel P. Sutherlin ,  Zachary K. Sweeney

IPC分类号： A61K31/535

CPC分类号： C07D513/04 ,  C07D487/04 ,  C07D491/04 ,  C07D495/04

摘要： Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, or (iv) X1 is CR7 and X2 is O, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

摘要翻译： 式（I）和（Ib）化合物，其中（i）X1为N，X 2为S，（ii）X1为CR7，X2为S，（iii）X1为N，X2为NR2，或（iv）X1为CR7， X 2为O，包括立体异构体，互变异构体，代谢物及其药学上可接受的盐，可用于抑制PI3K的δ同种型，以及用于治疗由脂质激酶如炎症，免疫学和癌症介导的病症。 公开了使用式I化合物在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

公开(公告)号：US08440651B2

公开(公告)日：2013-05-14

申请号：US13030246

申请日：2011-02-18

申请人： Georgette Castanedo ,  Bryan Chan ,  Matthew C. Lucas ,  Brian Safina ,  Daniel P. Sutherlin ,  Zachary Sweeney

发明人： Georgette Castanedo ,  Bryan Chan ,  Matthew C. Lucas ,  Brian Safina ,  Daniel P. Sutherlin ,  Zachary Sweeney

IPC分类号： A61K31/397 ,  A61K31/5377 ,  C07D413/14

CPC分类号： C07D471/04 ,  C07D491/107

摘要： Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

摘要翻译： 式I化合物，包括立体异构体，几何异构体，互变异构体，代谢物及其药学上可接受的盐，可用于抑制PI3K的δ同种型，以及用于治疗由脂质激酶如炎症，免疫学障碍和癌症介导的病症。 公开了使用式I化合物在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

公开(公告)号：US20110207713A1

公开(公告)日：2011-08-25

申请号：US13030246

申请日：2011-02-18

申请人： Georgette Castanedo ,  Bryan Chan ,  Matthew C. Lucas ,  Brian Safina ,  Daniel P. Sutherlin ,  Zachary Sweeney

发明人： Georgette Castanedo ,  Bryan Chan ,  Matthew C. Lucas ,  Brian Safina ,  Daniel P. Sutherlin ,  Zachary Sweeney

IPC分类号： A61K31/397 ,  C07D413/14 ,  A61K31/5377 ,  A61P19/02 ,  A61P29/00 ,  A61P9/00 ,  A61P35/00 ,  A61P31/12 ,  A61P25/00 ,  A61P37/06 ,  A61P1/04 ,  A61P25/28 ,  A61P11/00 ,  A61P17/06 ,  A61P3/10

CPC分类号： C07D471/04 ,  C07D491/107

摘要： Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

摘要翻译： 式I化合物，包括立体异构体，几何异构体，互变异构体，代谢物及其药学上可接受的盐，可用于抑制PI3K的δ同种型，以及用于治疗由脂质激酶如炎症，免疫学障碍和癌症介导的病症。 公开了使用式I化合物在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

公开(公告)号：US20110201599A1

公开(公告)日：2011-08-18

申请号：US13002195

申请日：2009-07-02

申请人： Suleyman Bahceci ,  Bryan Chan ,  Diva Sze-Ming Chan ,  Jeff Chen ,  Timothy Patrick Forsyth ,  Maurizio Franzini ,  Vasu Jammalamadaka ,  Joon Won Jeong ,  Lisa Renee Jones ,  Ryan Michael Kelley ,  Moon Hwan Kim ,  James W. Leahy ,  Morrison B. Mac ,  Robin Tammie Noguchi ,  Pallavi Rao ,  Brian Hugh Ridgway ,  Wei Xu ,  Yong Wang

发明人： Suleyman Bahceci ,  Bryan Chan ,  Diva Sze-Ming Chan ,  Jeff Chen ,  Timothy Patrick Forsyth ,  Maurizio Franzini ,  Vasu Jammalamadaka ,  Joon Won Jeong ,  Lisa Renee Jones ,  Ryan Michael Kelley ,  Moon Hwan Kim ,  James W. Leahy ,  Morrison B. Mac ,  Robin Tammie Noguchi ,  Pallavi Rao ,  Brian Hugh Ridgway ,  Wei Xu ,  Yong Wang

IPC分类号： A61K31/55 ,  C07D471/04 ,  C07D401/14 ,  C07D403/14 ,  C07D413/00 ,  C07D413/14 ,  C12N5/071 ,  A61K31/437 ,  A61K31/505 ,  A61K31/497 ,  A61K31/5377 ,  A61P35/00 ,  A61P35/02 ,  A61P37/00

CPC分类号： C07D487/04 ,  C07D471/04 ,  C07D519/00

摘要： A compound according to Formula I: or a pharmaceutically-acceptable salt thereof, wherein R1, R3, A, B and D are as defined in the specification; pharmaceutical compositions thereof, and methods of use thereof.

摘要翻译： 根据式I的化合物或其药学上可接受的盐，其中R 1，R 3，A，B和D如说明书中所定义; 其药物组合物及其使用方法。

公开(公告)号：US20110175875A1

公开(公告)日：2011-07-21

申请号：US13004763

申请日：2011-01-11

申请人： Craig Lin ,  Bryan Chan

发明人： Craig Lin ,  Bryan Chan

IPC分类号： G09G5/00 ,  G09G3/34

CPC分类号： G09G3/344 ,  G09G2300/08 ,  G09G2310/06

摘要： The present invention is directed to driving waveforms and a driving method for an electrophoretic display. The method and waveforms have the advantage that the changes in the driving voltages due to the shift are minimized. In addition, the overall driving time for the waveforms is also shortened due to the shortened driving frames. There are no additional data points required as the number of the driving frames remains the same. Therefore, the power consumption is nearly identical with the waveform having driving frames of a fixed frame time.

摘要翻译： 本发明涉及电泳显示器的驱动波形和驱动方法。 该方法和波形的优点在于，由于偏移导致的驱动电压的变化被最小化。 此外，由于缩短的驱动帧，波形的整体驱动时间也缩短。 由于驱动帧的数量保持不变，所以不需要额外的数据点。 因此，与具有固定帧时间的驱动帧的波形的功耗几乎相同。

公开(公告)号：US09460666B2

公开(公告)日：2016-10-04

申请号：US12772330

申请日：2010-05-03

申请人： Robert Sprague ,  Bryan Chan ,  Tin Pham ,  Craig Lin ,  Manasa Peri

发明人： Robert Sprague ,  Bryan Chan ,  Tin Pham ,  Craig Lin ,  Manasa Peri

IPC分类号： G09F9/302 ,  G09G3/20 ,  G02F1/1347 ,  E04D13/08 ,  G01R13/02 ,  H04B7/06 ,  G09G3/34

CPC分类号： G09G3/2003 ,  G09G3/344 ,  G09G3/3446 ,  G09G2300/0452 ,  G09G2310/061 ,  G09G2310/068 ,  G09G2320/0252

摘要： This application is directed to driving methods for electrophoretic displays. The driving methods and waveforms have the advantage that they provide a clean and smooth transition from one image to another image, without flashing or other undesired visual interruptions. The methods also provide faster image transitions. In an embodiment, a method drives a display device from a first image to a second image wherein images of a first color are displayed with a background of a second color, which method comprises driving pixels of the first color directly to the second color before driving pixels of the second color directly to the first color.

摘要翻译： 本申请涉及电泳显示器的驱动方法。 驱动方法和波形的优点在于，它们可以从一个图像到另一个图像提供干净平滑的过渡，而不会发生闪烁或其他不期望的视觉中断。 这些方法也提供了更快的图像转换。 在一个实施例中，一种方法将显示设备从第一图像驱动到第二图像，其中以第二颜色的背景显示第一颜色的图像，该方法包括在驾驶之前将第一颜色的像素直接驱动到第二颜色 第二种颜色的像素直接到第一种颜色。

公开(公告)号：US11049463B2

公开(公告)日：2021-06-29

申请号：US13004763

申请日：2011-01-11

申请人： Craig Lin ,  Bryan Chan

发明人： Craig Lin ,  Bryan Chan

IPC分类号： G09G3/34

摘要： The present invention is directed to driving waveforms and a driving method for an electrophoretic display. The method and waveforms have the advantage that the changes in the driving voltages due to the shift are minimized. In addition, the overall driving time for the waveforms is also shortened due to the shortened driving frames. There are no additional data points required as the number of the driving frames remains the same. Therefore, the power consumption is nearly identical with the waveform having driving frames of a fixed frame time.